IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting

Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist

(2018) Akira Shibata et al.   BIOCHEMICAL PHARMACOLOGY

882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study

(2018) William J. Sandborn et al.   GASTROENTEROLOGY

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease

(2018) Heike Schmitt et al.   GUT

Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rβ1

(2018) Yehudi Bloch et al.   IMMUNITY

P759 Ustekinumab as rescue treatment in therapy-refractory or -intolerant ulcerative colitis

(2018) T Ochsenkühn et al.   Journal of Crohns & Colitis

P035 Serum markers predict outcome to ustekinumab in patients with refractory Crohn’s disease and provide insides in the mechanism of action

(2018) B Verstockt et al.   Journal of Crohns & Colitis

CX3CR1+mononuclear phagocytes control immunity to intestinal fungi

(2018) Irina Leonardi et al.   SCIENCE

Cytokine Networks between Innate Lymphoid Cells and Myeloid Cells

(2018) Arthur Mortha et al.   Frontiers in Immunology

Divergent Roles of Interferon-γ and Innate Lymphoid Cells in Innate and Adaptive Immune Cell-Mediated Intestinal Inflammation

(2018) Jennifer Brasseit et al.   Frontiers in Immunology

c-MAF-dependent regulatory T cells mediate immunological tolerance to a gut pathobiont

(2018) Mo Xu et al.   NATURE

Targeting JAK-STAT signal transduction in IBD

(2018) Christoffer Soendergaard et al.   PHARMACOLOGY & THERAPEUTICS

The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Tracks with Efficacy in a Preclinical Model of IBD

(2017) Xiaoli Cheng et al.   GASTROENTEROLOGY

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

(2017) Bruce E. Sands et al.   GASTROENTEROLOGY

Dynamic balance between master transcription factors determines the fates and functions of CD4 T cell and innate lymphoid cell subsets

(2017) Difeng Fang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7

(2017) Yang Luo et al.   NATURE GENETICS

The IBD interactome: an integrated view of aetiology, pathogenesis and therapy

(2017) Heitor S. P. de Souza et al.   Nature Reviews Gastroenterology & Hepatology

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

(2016) Stephan R Targan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

Regulation of group 2 innate lymphoid cells

(2016) Claudia U. Duerr et al.   CYTOKINE

Ustekinumab for the Treatment of Refractory Crohnʼs Disease

(2016) Sam Khorrami et al.   INFLAMMATORY BOWEL DISEASES

IL23R (Interleukin 23 Receptor) Variants Protective against Inflammatory Bowel Diseases (IBD) Display Loss of Function due to Impaired Protein Stability and Intracellular Trafficking

(2016) Durga Sivanesan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study

(2016) Isabelle Cleynen et al.   LANCET

Epigenetic regulation of the expression of Il12 and Il23 and autoimmune inflammation by the deubiquitinase Trabid

(2016) Jin Jin et al.   NATURE IMMUNOLOGY

Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis

(2016) Christoph S N Klose et al.   NATURE IMMUNOLOGY

Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells

(2016) David R Withers et al.   NATURE MEDICINE

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-17 in Chronic Inflammation: From Discovery to Targeting

(2016) Audrey Beringer et al.   TRENDS IN MOLECULAR MEDICINE

T-bet is a key modulator of IL-23-driven pathogenic CD4+ T cell responses in the intestine

(2016) Thomas Krausgruber et al.   Nature Communications

Epithelial IL-23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation

(2016) Konrad Aden et al.   Cell Reports

UEG Week 2016 Oral Presentations

(2016)   United European Gastroenterology Journal

Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells

(2015) Koji Atarashi et al.   CELL

Genetics of Inflammatory Bowel Diseases

(2015) Dermot P.B. McGovern et al.   GASTROENTEROLOGY

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

(2015) Walter Reinisch et al.   GUT

Interleukin-12 and -23 Control Plasticity of CD127+ Group 1 and Group 3 Innate Lymphoid Cells in the Intestinal Lamina Propria

(2015) Jochem H. Bernink et al.   IMMUNITY

Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions

(2015) Dhavalkumar D. Patel et al.   IMMUNITY

European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

(2015) A. Nast et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets

(2015) Michelle L Robinette et al.   NATURE IMMUNOLOGY

IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

(2015) Michele W L Teng et al.   NATURE MEDICINE

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differentiation of Type 1 ILCs from a Common Progenitor to All Helper-like Innate Lymphoid Cell Lineages

(2014) Christoph S.N. Klose et al.   CELL

Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy

(2014) Raquel Franco Leal et al.   GUT

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Microbiota-Dependent Crosstalk Between Macrophages and ILC3 Promotes Intestinal Homeostasis

(2014) A. Mortha et al.   SCIENCE

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

(2013) Cornelia Tillack et al.   GUT

Intraepithelial Type 1 Innate Lymphoid Cells Are a Unique Subset of IL-12- and IL-15-Responsive IFN-γ-Producing Cells

(2013) Anja Fuchs et al.   IMMUNITY

Increased Prevalence of Circulating Novel IL-17 Secreting Foxp3 Expressing CD4+ T Cells and Defective Suppressive Function of Circulating Foxp3+ Regulatory Cells Support Plasticity Between Th17 and Regulatory T Cells in Inflammatory Bowel Disease Patients

(2013) Aito Ueno et al.   INFLAMMATORY BOWEL DISEASES

Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohn’s Disease

(2013) Francesca Zorzi et al.   PLoS One

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Interleukin-27: Balancing Protective and Pathological Immunity

(2012) Christopher A. Hunter et al.   IMMUNITY

Cutting Edge: A Variant of the IL-23R Gene Associated with Inflammatory Bowel Disease Induces Loss of MicroRNA Regulation and Enhanced Protein Production

(2012) A. Zwiers et al.   JOURNAL OF IMMUNOLOGY

Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease

(2012) Luke Jostins et al.   NATURE

The composition and signaling of the IL-35 receptor are unconventional

(2012) Lauren W Collison et al.   NATURE IMMUNOLOGY

IL-12 family cytokines: immunological playmakers

(2012) Dario A A Vignali et al.   NATURE IMMUNOLOGY

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interactions Between Commensal Fungi and the C-Type Lectin Receptor Dectin-1 Influence Colitis

(2012) I. D. Iliev et al.   SCIENCE

Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases

(2011) Warren Strober et al.   GASTROENTEROLOGY

Role of Interleukin-23 (IL-23) Receptor Signaling for IL-17 Responses in Human Lyme Disease

(2011) Marije Oosting et al.   INFECTION AND IMMUNITY

Compartmentalized Expression of Th1 and Th17 Cytokines in Pediatric Inflammatory Bowel Diseases

(2011) J. Verdier et al.   INFLAMMATORY BOWEL DISEASES

IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease

(2011) Alessandra Geremia et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IL-23 Is Critical for Induction of Arthritis, Osteoclast Formation, and Maintenance of Bone Mass

(2011) I. E. Adamopoulos et al.   JOURNAL OF IMMUNOLOGY

Fate mapping of IL-17-producing T cells in inflammatory responses

(2011) Keiji Hirota et al.   NATURE IMMUNOLOGY

The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans

(2011) Paola Di Meglio et al.   PLoS One

Functional Studies on the IBD Susceptibility Gene IL23R Implicate Reduced Receptor Function in the Protective Genetic Variant R381Q

(2011) Svetlana Pidasheva et al.   PLoS One

Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses

(2011) R. Sarin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity

(2011) A. Puel et al.   SCIENCE

T helper 17 cell heterogeneity and pathogenicity in autoimmune disease

(2011) Kamran Ghoreschi et al.   TRENDS IN IMMUNOLOGY

CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signals

(2010) Linda Y. Sender et al.   MOLECULAR IMMUNOLOGY

Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology

(2010) Sofia Buonocore et al.   NATURE

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

(2010) Andre Franke et al.   NATURE GENETICS

Candida albicans Colonization and ASCA in Familial Crohn's Disease

(2009) Annie Standaert-Vitse et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

IL-17-producing human peripheral regulatory T cells retain suppressive function

(2009) G. Beriou et al.   BLOOD

Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria

(2009) Ivaylo I. Ivanov et al.   CELL

Differential regulation of interleukin 17 and interferon   production in inflammatory bowel disease

(2009) L. Rovedatti et al.   GUT

Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

(2009) Walter Reinisch et al.   INFLAMMATORY BOWEL DISEASES

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease

(2008) T Kobayashi et al.   GUT

Signal Transducer and Activator of Transcription 4 Is Required for the Transcription Factor T-bet to Promote T Helper 1 Cell-Fate Determination

(2008) Vivian T. Thieu et al.   IMMUNITY

Regulation of inflammatory responses by IL-17F

(2008) Xuexian O. Yang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IL-12 family members in experimental colitis

(2008) M F Neurath   Mucosal Immunology

IL-23 and Th17 cytokines in intestinal homeostasis

(2008) K J Maloy et al.   Mucosal Immunology

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

(2008) Jeffrey C Barrett et al.   NATURE GENETICS

Linking genetic susceptibility to Crohnʼs disease with Th17 cell function: IL-22 serum levels are increased in Crohnʼs disease and correlate with disease activity and IL23R genotype status

(2007) Silke Schmechel et al.   INFLAMMATORY BOWEL DISEASES